Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447480 | 0.94 | FFAR1 (0.43) | FFAR1PTGDR2MMP2MMP12CYP2C9 | |
| SCHEMBL6447485 | 0.94 | FFAR1 (0.43) | FFAR1PTGDR2MMP2MMP12CYP2C9 | |
| SCHEMBL6446075 | 0.85 | FFAR1 (0.50) | FFAR1PTGDR2MMP2MMP12ALOX15 | |
| SCHEMBL75765 | 0.78 | PTGDR2 (0.51) | FFAR1PTGDR2MMP2MMP12CYP2C9 | |
| SCHEMBL30852830 | 0.75 | MMP2 (0.55) | FFAR1MMP2MMP12ALOX15KDM4E | |
| SCHEMBL3634841 | 0.73 | HTT (0.58) | FFAR1MMP2MMP12CYP2C9KDM4E | |
| SCHEMBL1778144 | 0.73 | FFAR1 (0.71) | FFAR1PTGDR2ALOX15ALDH1A1 | |
| SCHEMBL14514021 | 0.73 | FFAR1 (0.53) | FFAR1 | |
| SCHEMBL4683194 | 0.71 | FFAR1 (0.57) | FFAR1PTGDR2CYP2C9ALOX15ALOX5 | |
| SCHEMBL1276464 | 0.71 | CYP1A2 (0.56) | MMP2MMP12CYP2C9KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960588-B1 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2005-11-01 | — | — | US | disclosed |
| US-20050143536-A1 | Substituted indenyl metal complexes and polymerization process | DOW GLOBAL TECHNOLOGIES LLC | 2005-06-30 | — | — | US | disclosed |
| EP-1216236-A1 | TRYPTASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019809-A1 | TRYPTASE INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143536-A1 | Substituted indenyl metal complexes and polymerization process | ORC3, SOD1, YAP1 | FFAR1 3727/4885PTGDR2 4046/4885MMP2 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.